J&J, Novartis Fined $22.4M Over Pay-For-Delay Deal

Law360, New York (December 10, 2013, 1:06 PM EST) -- Drugmakers Johnson & Johnson and Novartis AG on Tuesday were hit with a total of €16.3 million ($22.4 million) in fines by European regulators for entering into an anti-competitive agreement to delay the introduction of a generic painkiller in the Netherlands.

The European Commission said in 2005 that the respective Dutch subsidiaries of Novartis and J&J entered into a deal to prevent the entry of a generic version of J&J's fentanyl, after the protection on its brand-name fentanyl depot patch expired in the Netherlands, just as...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.